Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Keclon SA currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct art unit, indicating a focused technical review of the company's biological or pharmaceutical innovations. The prosecution is overseen by 1 distinct examiner, centralizing the company's current interactions with the patent office. The busiest examiner for the portfolio is MONSHIPOURI, MARYAM, who is managing 1 pending office action.
This workload represents the full extent of the company's active prosecution. With only 1 examiner and 1 art unit involved, the company's current experience is highly specific. Practitioners can focus their strategy on the individual examination style of this 1 examiner. The data shows no current diversification across different examiners or technical divisions for this portfolio. This concentration means that the outcome of the current filing depends entirely on the evaluation of this specific official within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.2% | +37.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727871 | MUTATED PHOSPHOLIPASE C ENZYME | MONSHIPOURI, MARYAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727871 | MUTATED PHOSPHOLIPASE C ENZYME | MONSHIPOURI, MARYAM | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727871 | MUTATED PHOSPHOLIPASE C ENZYME | MONSHIPOURI, MARYAM | 1651 | §102§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKeclon SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maryam Monshipouri has the most, with 1 of Keclon SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
